Log In
BCIQ
Print this Print this
 

LP-590

  Manage Alerts
Collapse Summary General Information
Company Locus Pharmaceuticals Inc.
DescriptionOral inhibitor of Tie-2, Ret, and p38 kinases
Molecular Target Tyrosine kinase receptor 2 (Tie2) ; Ret proto-oncogene (RET)
Mechanism of ActionMAP kinase (p38) inhibitor; RET inhibitor; Tyrosine kinase receptor 2 (Tie2) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today